Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells

Gene Therapy

Volumn 10, Issue 11 SPEC., 2003, Pages 983-990

  Wakimoto, H ^a   Johnson, P R ^b   Knipe, D M ^b   Chiocca, E A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON; BETA INTERFERON; CHEMOKINE; COMPLEMENT; CYCLOPHOSPHAMIDE; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERFERON; INTERLEUKIN 15; INTERLEUKIN 18; NITRIC OXIDE; ONCOLYTIC VIRUS; PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR; COMPLEMENT INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

BRAIN CANCER; CELL KILLING; CENTRAL NERVOUS SYSTEM; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS 1; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; MACROPHAGE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; T LYMPHOCYTE; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS INFECTION; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE; ANIMAL; BRAIN TUMOR; GENE THERAPY; GENE VECTOR; HERPES SIMPLEX; IMMUNOLOGY; METHODOLOGY; NEOPLASM; VIROLOGY; VIRUS;

DNA VIRUSES; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

ANIMALS; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; CYCLOPHOSPHAMIDE; GENE THERAPY; GENETIC VECTORS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; VIRUS REPLICATION; VIRUSES;

EID: 0038467368     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302038     Document Type: Review

References (82)

1. Chiocca EA, Smith ER. Oncolytic viruses as novel anticancer agents: turning one scourge against another [In Process Citation]. Expert Opin Investig Drugs [MEDLINE record in process], 2000; 9: 311-327.
2. Markert JM et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial [see comments]. Gene Therapy 2000; 7: 867-874.
3. Rampling R et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Therapy 2000; 7: 859-866.
4. Whitley RJ. Herpes simplex viruses. In: Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE (eds.), Fields Virology, 3rd edn, Vol 2, pp 2297-2342. Lipincott-Raven: Philadelphia/New York, 1996.
5. Carroll MC, Prodeus AP. Linkages of innate and adaptive immunity. Curr Opin Immunol 1998; 10: 36-40.
6. Verschoor A, Brockman MA, Knipe DM, Carroll MC. Cutting edge: myeloid complement C3 enhances the humoral response to peripheral viral infection. J Immunol 2001; 167: 2446-2451.
7. Da Costa XJ et al. Humoral response to herpes simplex virus is complement-dependent. Proc Natl Acad Sci USA 1999; 96: 12708-12712.
8. Siegal FP et al. The nature of the principal type 1 interferon-producing cells in hman blood. Science 1999; 284: 1835-1837.
9. Kadowaki N. Antonenko S, Lau JY, Liu YJ. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 2000; 192: 219-226.
10. Bukowski JF, Morista CT, Brenner MB. Recognition and destruction of virus-infected cells by human gamma delta CTL. J Immunol 1994; 153: 5133-5140.
11. Johnson RM et al. A murine CD4-, CD8- T cell receptor-gamma delta T lymphocyte clone specific for herpes simplex virus glycoprotein I. J Immunol 1992; 148: 983-988.
12. Selin LK et al. Innate immunity to viruses: control of vaccinia virus infection by gamma delta T cells. J Immunol 2001; 166: 6784-6794.
13. Melchjorsen J, Pedersen FS, Mogensen SC, Paludan SR. Herpes simplex virus selectively induces expression of the CC chemokine RANTES/CCL5 in macrophages through a mechanism dependent on PKR and ICP0. J Virol 2002; 76: 2780-2788.
14. Fawaz LM, Sharif-Askari E, Menezes J. Up-regulation of NK cytotoxic activity via IL-15 induction by different viruses: a comparative study. J Immunol 1999; 163: 4473-4480.
15. Fujioka N et al. Interleukin-18 protects mice against acute herpes simplex virus type 1 infection viruses: a comparative study. J Virol 1999; 73: 2401-2409.
16. Feduchi E, Alonso MA, Carrasco L. Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus. J Virol 1989; 63: 1354-1359.
17. Croen KD. Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication. J Clin Invest 1993; 91: 2446-2452.
18. Ahmad A, Sharif-Askari E, Fawaz L, Menezes J. Innate immune response of the human host to exposure with herpes simplex virus type 1: in vitro control of the virus infection by enhanced natural killer activity via interleukin-15 induction. J Virol 2000; 74: 7196-7203.
19. Karupiah G et al. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 1993; 261: 1445-1448.
20. Kodukula P et al. Macrophage control of herpes simplex virus type 1 replication in the peripheral nervous system. J Immunol 1999; 162: 2895-2905.
21. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
22. Lubinski JM et al. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J Virol 1998; 72: 8257-8263.
23. Lubinski J et al. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC [published erratum appears in J Exp Med 2000 Feb 21;191(4):following 746]. J Exp Med 1999; 190: 1637-1646.
24. Costa J, Rabson AS, Yee C, Tralka TS. Immunoglobulin binding to herpes virus-induced Fc receptors inhibits virus growth. Nature 1977; 269: 251-252.
25. Dubin G et al. The role of herpes simplex virus glycoproteins in immune evasion. Curr Top Microbiol Immunol, 1992; 179: 111-120.
26. Friedman HM et al. Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type I [In Process Citation]. J Immunol 2000; 165: 4528-4536 [MEDLINE record in process].
27. Friedman HM et al. Immune evasion properties of herpes simplex virus type 1 glycoprotein gC. J Virol 1996; 70: 4253-4260.
28. Hill A et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995; 375: 411-415.
29. Salio M, Cella M, Suter M, Lanzavecchia A. Inhibition of dendritic cell maturation by herpes simplex virus. Eur J Immunol 1999; 29: 3245-3253.
30. Leib DA. Counteraction of interferon-induced antiviral responses by herpes simplex viruses. Curr Top Microbiol Immunol 2002; 269: 171-185.
31. Suzutani T et al. The role of the UL41 gene of herpes simplex virus type 1 in evasion of non-specific host defence mechanisms during primary infection. J Gen Virol 2000; 81: 1763-1771.
32. Todo T et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 1999; 10: 2741-2755.
33. Song WC, Sarrias MR, Lambris JD. Complement and innate immunity. Immunopharmacology 2000; 49: 187-198.
34. Sastry K et al. Molecular characterization of the mouse mannose-binding proteins. The mannose-binding protein A but not C is an acute phase reactant. J Immunol 1991; 147: 692-697.
35. Kawasaki N, Kawasaki T, Yamashina I. Isolation and characterization of a mannan-binding protein from human serum. J Biochem (Tokyo) 1983; 94: 937-947.
36. Hansen S et al. Purification and characterization of two mannan-binding lectins from mouse serum. J Immunol 2000; 164: 2610-2618.
37. Haurum JS et al. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. Aids 1993; 7: 1307-1313.
38. Smiley ML, Friedman HM. Binding of complement component C3b to glycoprotein C is modulated by sialic acid on herpes simplex virus type 1-infected cells. J Virol 1985; 55: 857-861.
39. Friedman HM et al. Binding of complement component C3b to glycoprotein gC of herpes simplex virus type 1: mapping of gC-binding sites and demonstration of conserved C3b binding in low-passage clinical isolates. J Virol 1986; 60: 470-475.
40. Schellingerhout D et al. Mapping the in vivo distribution of herpes simplex virions. Hum Gene Ther 1998; 9: 1543-1549.
41. Schellingerhout D, Rainov NG, Breakefield XO, Weissleder R. Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Therapy 2000; 7: 1648-1655.
42. Yoon SS et al. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. Faseb J 2000; 14: 301-311.
43. Pawlik TM et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 2000; 60: 2790-2795.
44. Nakamura H et al. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 2001; 61: 5447-5452.
45. Nakamura et al. Regulation of herpes simplex virus gamma (1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest 2002; 109: 871-882.
46. Pawlik TM et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 2002; 95: 1171-1181.
47. Neuwelt EA, Pagel MA, Dix RD. Delivery of ultraviolet-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrier. J Neurosurg 1991; 74: 475-479.
48. Nilaver G et al. Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc Natl Acad Sci USA 1995; 92: 9829-9833.
49. Ikeda K et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999; 5: 881-887.
50. Wakimoto H et al. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther 2002; 5: 275-282.
51. Ikeda K et al. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 2000; 74: 4765-4775.
52. Welsh RM, O'Donnell CL, Reed DJ, Rother RP. Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses. J Virol 1998; 72: 4650-4656.
53. Welsh Jr RM, Cooper NR, Jensen FC, Oldstone MB. Human serum lyses RNA tumour viruses. Nature 1975; 257: 612-614.
54. Agrawal RS et al. Complement and anti-alpha-galactosyl natural antibody-mediated inactivation of murine retrovirus occurs in adult serum but not in umbilical cord serum. Gene Therapy 1999; 6: 146-148.
55. Rother RP et al. A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody. J Exp Med 1995; 182: 1345-1355.
56. Sokoloff AV et al. Specific recognition of protein carboxyterminal sequences by natural IgM antibodies in normal serum. Mole Ther 2001; 3: 821-830.
57. Boes M et al. critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med 1998; 188: 2381-2386.
58. Boes M et al. Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. J Immunol 1998; 160: 4776-4787.
59. Yokota S et al. Herpes simplex virus type 1 suppresses the interferon signaling pathway by inhibiting phosphorylation of STATs and janus kinases during an early infection stage. Virology 2001; 286: 119-124.
60. He B, Gross M, Roizman B. The gamma(1)3.45 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1997; 94: 843-848.
61. Leib DA et al. Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J Exp Med 1999; 189: 663-672.
62. Zamanian-Daryoush M, Mogensen TH, DiDonato JA, Williams BR. NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase. Mol Cell Biol 2000; 20: 1278-1290.
63. Deb A et al. RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway. J Immunol 2001; 166: 6170-6180.
64. Uetani K et al. Central role of double-stranded RNA-activated protein kinase in microbial induction of nitric oxide synthase. J Immunol 2000; 165: 988-996.
65. Geiger KD et al. Interferon-gamma protects against herpes simplex virus type 1-mediated neuronal death. Virology 1997; 238:189-197.
66. Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002; 61: 1013-1021.
67. Lindsberg PJ et al. Complement activation in the central nervous system following blood-brain barrier damage in man. Ann Neurol 1996; 40: 587-596.
68. Shinoura N et al. G. RNA expression of complement regulatory proteins in human brain tumors. Cancer Lett 1994; 86: 143-149.
69. Maenpaa A et al. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am J Pathol 1996; 148: 1139-1152.
70. Todo T et al. Viral shedding and biodistribution of G207, a multimutated conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther 2000; 2: 588-595 [Record as supplied by publisher].
71. Miller CG, Fraser NW. Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res 2000; 60: 5714-5722.
72. Delman KA et al. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy [In Process Citation]. Hum Gene Ther 2000; 11: 2465-2472 [MEDLINE record in process].
73. Chahlavi A et al. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Therapy 1999; 6: 1751-1758.
74. Huemer HP et al. Herpes simplex virus binds to human serum lipoprotein. Intervirology 1988; 29: 68-76.
75. Srinivas RV et al. Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs. Virology 1990; 176: 48-57.
76. Srinivas RV et al. Inhibition of virus-induced cell fusion by apolipoprotein A-I and its amphipathic peptide analogs. J Cell Biochem 1991; 45: 224-237.
77. Ash RJ. Butyrate-induced reversal of herpes simplex virus restriction in neuroblastoma cells. Virology 1986; 155: 584-592.
78. Thormar H et al. Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides. Antimicrob Agents Chemother 1987; 31: 27-31.
79. Johansson PJ, Kjellen L. Inhibition of herpes simplex virus growth caused by preparations of animal immunoglobulins is not dependent on Fc-Fc receptor interactions. Intervirology 1988; 29: 334-338.
80. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus counter-measures. J Gen Virol 2000; 81: 2341-2364.
81. Benencia F, Courreges MC. Nitric oxide and macrophage antiviral extrinsic activity. Immunology 1999; 98: 363-370.
82. Goldstein DJ, Weller SK, An ICP6: lacZ insertional mutagen is used to demonstrate that the UL52 gene of herpes simplex virus type 1 is required for virus growth and DNA synthesis. J Virol 1988; 62: 2970-2977.